{
    "info": {
        "nct_id": "NCT04038502",
        "official_title": "An Open-label, Multicenter Phase II Study to Compare the Efficacy of Carboplatin as First-line Followed by Second-line Olaparib Versus Olaparib as First-line Followed by Second-line Carboplatin in the Treatment of Patients With Castration Resistant Prostate Cancer Containing Homologous Recombination Deficiency",
        "inclusion_criteria": "1. Signed study informed consent form (ICF) and HIPAA authorization form\n2. Male age > 18 years\n3. Diagnosis of prostate cancer (pure small-cell histology or pure high-grade neuroendocrine histology are excluded; neuroendocrine differentiation is allowed)\n4. Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy. Patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy\n5. mCRPC as defined by serum testosterone < 50 ng/ml (for patients on GnRH analogues or antagonists) and at least one of the following:\n\n   * PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions at least 1 week apart\n   * Evaluable disease progression by modified RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)\n   * Progression of metastatic bone disease on bone scan, CT or MRI with > 2 new lesions\n6. Prior therapy with abiraterone acetate, enzalutamide, apalutamide, or darolutamide\n7. Eastern Cooperative Oncology Group (ECOG) Performance Status of < 2 (see Appendix 3, ECOG Grading Scale)\n8. Results of previous standard DNA testing, or previous research testing, which confirms RAD51B, RAD51C, RAD51D, or RAD54L mutations (see Introduction, Section 2 for study design and previous research on targeted therapy) from primary, metastatic tumor or circulating tumor DNA, or pathogenic/likely pathogenic germline variant as assessed by a CLIA certified laboratory level assay for DNA sequencing.\n9. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:\n\n   * Hemoglobin > 10.0 g/dL\n   * Absolute neutrophil count (ANC) > 1.5 x 109/L\n   * Platelet count > 100 x 109/L\n   * Total bilirubin < 1.5 x institutional upper limit of normal (ULN)\n   * Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) < 2.5 x institutional upper limit of normal unless liver metastases are present in which case, they must be < 5x ULN\n   * Patients must have creatinine clearance estimated using the Cockcroft-Gault equation of >51 mL/min: Estimated creatinine clearance =(140-age [years]) x weight (kg))/ (serum creatinine (mg/dL) x 72)\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Currently receiving active therapy for other neoplastic disorder(s)\n2. Concurrent enrollment in another clinical investigational drug or device study\n3. Histologic evidence of small cell carcinoma (morphology alone - immunohistochemical evidence of neuroendocrine differentiation without morphologic evidence is not exclusionary)\n4. Prior treatment with platinum, mitoxantrone or PARP inhibitor for castration resistant prostate cancer\n5. Known parenchymal brain metastasis\n6. Active or symptomatic viral hepatitis or chronic liver disease AST or ALT > 2.5 x ULN or total bilirubin > ULN (unless Gilbert's syndrome is the etiology of hyperbilirubinemia)\n7. Subjects with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML\n8. Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks\n9. Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for phenobarbital and 3 weeks for other agents\n10. Subjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of the study medication\n11. Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 35 % at baseline\n12. Treatment with an investigational therapeutic within 30 days of Cycle-1\n13. Presence of dementia, psychiatric illness, and/or social situations limiting compliance with study requirements or understanding HIPAA authorization and/or giving of informed consent\n14. Any condition(s), medical or otherwise, which, in the opinion of the Investigators, would jeopardize either the patient or the integrity of the data obtained.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "2. Male age > 18 years",
            "criterions": [
                {
                    "exact_snippets": "Male",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "age > 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin < 1.5 x institutional upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin < 1.5 x institutional upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x institutional upper limit of normal (ULN)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) < 2.5 x institutional upper limit of normal unless liver metastases are present in which case, they must be < 5x ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) < 2.5 x institutional upper limit of normal unless liver metastases are present in which case, they must be < 5x ULN",
                    "criterion": "AST and ALT levels",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 2.5,
                                        "unit": "x institutional upper limit of normal"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity_with_liver_metastases",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "x institutional upper limit of normal"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progression of metastatic bone disease on bone scan, CT or MRI with > 2 new lesions",
            "criterions": [
                {
                    "exact_snippets": "Progression of metastatic bone disease on bone scan, CT or MRI",
                    "criterion": "metastatic bone disease progression",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": [
                                "bone scan",
                                "CT",
                                "MRI"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "> 2 new lesions",
                    "criterion": "number of new lesions",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "lesions"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count > 100 x 109/L",
            "criterions": [
                {
                    "exact_snippets": "Platelet count > 100 x 109/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Signed study informed consent form (ICF) and HIPAA authorization form",
            "criterions": [
                {
                    "exact_snippets": "Signed study informed consent form (ICF)",
                    "criterion": "study informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HIPAA authorization form",
                    "criterion": "HIPAA authorization form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:",
            "criterions": [
                {
                    "exact_snippets": "Patients must have normal organ and bone marrow function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must have normal organ and bone marrow function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    ]
                },
                {
                    "exact_snippets": "measured within 28 days prior to administration of study treatment",
                    "criterion": "organ and bone marrow function measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "measurement timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to administration of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy. Patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy",
            "criterions": [
                {
                    "exact_snippets": "Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy",
                    "criterion": "gonadal androgen deprivation therapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        },
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "GnRH analogue",
                                "GnRH antagonist",
                                "orchiectomy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy",
                    "criterion": "GnRH analogue/antagonist therapy (if no orchiectomy)",
                    "requirements": [
                        {
                            "requirement_type": "maintenance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have creatinine clearance estimated using the Cockcroft-Gault equation of >51 mL/min: Estimated creatinine clearance =(140-age [years]) x weight (kg))/ (serum creatinine (mg/dL) x 72)",
            "criterions": [
                {
                    "exact_snippets": "creatinine clearance estimated using the Cockcroft-Gault equation of >51 mL/min",
                    "criterion": "creatinine clearance (Cockcroft-Gault)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 51,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Prior therapy with abiraterone acetate, enzalutamide, apalutamide, or darolutamide",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy with abiraterone acetate",
                    "criterion": "prior therapy with abiraterone acetate",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior therapy with ... enzalutamide",
                    "criterion": "prior therapy with enzalutamide",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior therapy with ... apalutamide",
                    "criterion": "prior therapy with apalutamide",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior therapy with ... darolutamide",
                    "criterion": "prior therapy with darolutamide",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. mCRPC as defined by serum testosterone < 50 ng/ml (for patients on GnRH analogues or antagonists) and at least one of the following:",
            "criterions": [
                {
                    "exact_snippets": "mCRPC as defined by serum testosterone < 50 ng/ml (for patients on GnRH analogues or antagonists)",
                    "criterion": "serum testosterone",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/ml"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients on GnRH analogues or antagonists",
                    "criterion": "GnRH analogue or antagonist therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin > 10.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin > 10.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 10.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Diagnosis of prostate cancer (pure small-cell histology or pure high-grade neuroendocrine histology are excluded; neuroendocrine differentiation is allowed)",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of prostate cancer",
                    "criterion": "prostate cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pure small-cell histology ... are excluded",
                    "criterion": "pure small-cell histology",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "pure high-grade neuroendocrine histology are excluded",
                    "criterion": "pure high-grade neuroendocrine histology",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "neuroendocrine differentiation is allowed",
                    "criterion": "neuroendocrine differentiation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Results of previous standard DNA testing, or previous research testing, which confirms RAD51B, RAD51C, RAD51D, or RAD54L mutations (see Introduction, Section 2 for study design and previous research on targeted therapy) from primary, metastatic tumor or circulating tumor DNA, or pathogenic/likely pathogenic germline variant as assessed by a CLIA certified laboratory level assay for DNA sequencing.",
            "criterions": [
                {
                    "exact_snippets": "Results of previous standard DNA testing, or previous research testing, which confirms RAD51B, RAD51C, RAD51D, or RAD54L mutations",
                    "criterion": "RAD51B, RAD51C, RAD51D, or RAD54L mutations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "from primary, metastatic tumor or circulating tumor DNA",
                    "criterion": "source of DNA",
                    "requirements": [
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "primary tumor",
                                "metastatic tumor",
                                "circulating tumor DNA"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "pathogenic/likely pathogenic germline variant as assessed by a CLIA certified laboratory level assay for DNA sequencing",
                    "criterion": "germline variant pathogenicity",
                    "requirements": [
                        {
                            "requirement_type": "pathogenicity",
                            "expected_value": [
                                "pathogenic",
                                "likely pathogenic"
                            ]
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "CLIA certified laboratory level assay for DNA sequencing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Eastern Cooperative Oncology Group (ECOG) Performance Status of < 2 (see Appendix 3, ECOG Grading Scale)",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of < 2",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions at least 1 week apart",
            "criterions": [
                {
                    "exact_snippets": "PSA level of at least 2 ng/ml",
                    "criterion": "PSA level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "ng/ml"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "risen on at least 2 successive occasions at least 1 week apart",
                    "criterion": "PSA level",
                    "requirements": [
                        {
                            "requirement_type": "trend",
                            "expected_value": "rising"
                        },
                        {
                            "requirement_type": "number of successive occasions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "successive occasions"
                            }
                        },
                        {
                            "requirement_type": "interval between occasions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evaluable disease progression by modified RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)",
            "criterions": [
                {
                    "exact_snippets": "Evaluable disease progression by modified RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "evaluability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "modified RECIST 1.1"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "14. Any condition(s), medical or otherwise, which, in the opinion of the Investigators, would jeopardize either the patient or the integrity of the data obtained.",
            "criterions": [
                {
                    "exact_snippets": "Any condition(s), medical or otherwise, which, in the opinion of the Investigators, would jeopardize either the patient or the integrity of the data obtained.",
                    "criterion": "any condition jeopardizing patient safety or data integrity (per investigator judgment)",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Currently receiving active therapy for other neoplastic disorder(s)",
            "criterions": [
                {
                    "exact_snippets": "Currently receiving active therapy for other neoplastic disorder(s)",
                    "criterion": "active therapy for other neoplastic disorder(s)",
                    "requirements": [
                        {
                            "requirement_type": "current status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Prior treatment with platinum, mitoxantrone or PARP inhibitor for castration resistant prostate cancer",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with platinum, mitoxantrone or PARP inhibitor for castration resistant prostate cancer",
                    "criterion": "prior treatment with platinum for castration resistant prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with platinum, mitoxantrone or PARP inhibitor for castration resistant prostate cancer",
                    "criterion": "prior treatment with mitoxantrone for castration resistant prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with platinum, mitoxantrone or PARP inhibitor for castration resistant prostate cancer",
                    "criterion": "prior treatment with PARP inhibitor for castration resistant prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Known parenchymal brain metastasis",
            "criterions": [
                {
                    "exact_snippets": "Known parenchymal brain metastasis",
                    "criterion": "parenchymal brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness/status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 35 % at baseline",
            "criterions": [
                {
                    "exact_snippets": "myocardial infarction ... in the past 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history within time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "arterial thrombotic events in the past 6 months",
                    "criterion": "arterial thrombotic events",
                    "requirements": [
                        {
                            "requirement_type": "history within time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "severe or unstable angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "severe",
                                "unstable"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association (NYHA) Class II-IV heart disease",
                    "criterion": "NYHA heart disease class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NYHA class"
                            }
                        },
                        {
                            "requirement_type": "class",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac ejection fraction measurement of < 35 % at baseline",
                    "criterion": "cardiac ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "measurement",
                            "expected_value": {
                                "operator": "<",
                                "value": 35,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Subjects with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML",
            "criterions": [
                {
                    "exact_snippets": "Subjects with myelodysplastic syndrome/acute myeloid leukemia",
                    "criterion": "myelodysplastic syndrome or acute myeloid leukemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "features suggestive of MDS/AML",
                    "criterion": "features suggestive of myelodysplastic syndrome or acute myeloid leukemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Active or symptomatic viral hepatitis or chronic liver disease AST or ALT > 2.5 x ULN or total bilirubin > ULN (unless Gilbert's syndrome is the etiology of hyperbilirubinemia)",
            "criterions": [
                {
                    "exact_snippets": "Active or symptomatic viral hepatitis",
                    "criterion": "viral hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "activity or symptoms",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic liver disease",
                    "criterion": "chronic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "AST or ALT > 2.5 x ULN",
                    "criterion": "AST",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST or ALT > 2.5 x ULN",
                    "criterion": "ALT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin > ULN (unless Gilbert's syndrome is the etiology of hyperbilirubinemia)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless Gilbert's syndrome is the etiology of hyperbilirubinemia"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Histologic evidence of small cell carcinoma (morphology alone - immunohistochemical evidence of neuroendocrine differentiation without morphologic evidence is not exclusionary)",
            "criterions": [
                {
                    "exact_snippets": "Histologic evidence of small cell carcinoma (morphology alone",
                    "criterion": "small cell carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histologic evidence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "morphology",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immunohistochemical evidence of neuroendocrine differentiation without morphologic evidence is not exclusionary",
                    "criterion": "neuroendocrine differentiation",
                    "requirements": [
                        {
                            "requirement_type": "immunohistochemical evidence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "morphologic evidence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for phenobarbital and 3 weeks for other agents",
            "criterions": [
                {
                    "exact_snippets": "Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil)",
                    "criterion": "concomitant use of strong or moderate CYP3A inducers",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Presence of dementia, psychiatric illness, and/or social situations limiting compliance with study requirements or understanding HIPAA authorization and/or giving of informed consent",
            "criterions": [
                {
                    "exact_snippets": "Presence of dementia",
                    "criterion": "dementia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "social situations limiting compliance with study requirements",
                    "criterion": "social situations limiting compliance with study requirements",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "limiting compliance with study requirements",
                    "criterion": "ability to comply with study requirements",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "limiting ... understanding HIPAA authorization",
                    "criterion": "ability to understand HIPAA authorization",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "limiting ... giving of informed consent",
                    "criterion": "ability to give informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Concurrent enrollment in another clinical investigational drug or device study",
            "criterions": [
                {
                    "exact_snippets": "Concurrent enrollment in another clinical investigational drug or device study",
                    "criterion": "enrollment in another clinical investigational drug or device study",
                    "requirements": [
                        {
                            "requirement_type": "concurrent enrollment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks",
            "criterions": [
                {
                    "exact_snippets": "Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir)",
                    "criterion": "concomitant use of strong CYP3A inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Concomitant use of ... moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil)",
                    "criterion": "concomitant use of moderate CYP3A inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "The required washout period prior to starting olaparib is 2 weeks",
                    "criterion": "washout period for CYP3A inhibitors prior to olaparib",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Subjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of the study medication",
            "criterions": [
                {
                    "exact_snippets": "Subjects unable to swallow orally administered medication",
                    "criterion": "ability to swallow orally administered medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with gastrointestinal disorders likely to interfere with absorption of the study medication",
                    "criterion": "gastrointestinal disorders interfering with absorption of study medication",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Treatment with an investigational therapeutic within 30 days of Cycle-1",
            "criterions": [
                {
                    "exact_snippets": "Treatment with an investigational therapeutic within 30 days of Cycle-1",
                    "criterion": "treatment with investigational therapeutic",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days before Cycle-1"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Absolute neutrophil count (ANC) > 1.5 x 109/L",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) > 1.5 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}